Development of CMTM6 inhibitors: Modulation of PDL1 for cancer treatment
ImmuneNOVA aims to establish preclinical proof-of-concept in in vivo oncology models and in relevant patient-derived in vitro cell models for a novel immune checkpoint inhibitor targeting CMTM6. This inhibitor blocks a known immune checkpoint axis, PD-1/PD-L1, by decreasing cell surface expression of PD-L1, and so potentiates anti-tumour immunity. This novel inhibitor can be used to treat advanced forms of cancer, such as lung cancer, skin cancer (melanoma) and kidney cancer.
3 521 350.00€
Pharmaceutical Products / Drugs
Monoclonal Antibodies and Hybridomas